X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs J.B.CHEMICALS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES J.B.CHEMICALS DIVIS LABORATORIES/
J.B.CHEMICALS
 
P/E (TTM) x 34.4 17.1 201.8% View Chart
P/BV x 6.7 2.3 289.8% View Chart
Dividend Yield % 0.7 0.2 399.5%  

Financials

 DIVIS LABORATORIES   J.B.CHEMICALS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
J.B.CHEMICALS
Mar-16
DIVIS LABORATORIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,142318 358.9%   
Low Rs533200 267.2%   
Sales per share (Unadj.) Rs146.6148.0 99.1%  
Earnings per share (Unadj.) Rs33.019.1 173.1%  
Cash flow per share (Unadj.) Rs38.423.9 160.4%  
Dividends per share (Unadj.) Rs10.000.50 2,000.0%  
Dividend yield (eoy) %1.20.2 618.1%  
Book value per share (Unadj.) Rs222.8128.9 172.8%  
Shares outstanding (eoy) m265.4784.82 313.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.71.7 326.7%   
Avg P/E ratio x25.313.6 186.9%  
P/CF ratio (eoy) x21.810.8 201.8%  
Price / Book Value ratio x3.82.0 187.3%  
Dividend payout %30.32.6 1,155.3%   
Avg Mkt Cap Rs m222,31821,951 1,012.8%   
No. of employees `00010.82.7 393.6%   
Total wages/salary Rs m4,5611,841 247.7%   
Avg. sales/employee Rs Th3,616.04,590.9 78.8%   
Avg. wages/employee Rs Th423.8673.4 62.9%   
Avg. net profit/employee Rs Th814.9592.1 137.6%   
INCOME DATA
Net Sales Rs m38,91512,551 310.0%  
Other income Rs m1,134542 209.5%   
Total revenues Rs m40,04913,093 305.9%   
Gross profit Rs m12,6172,055 614.1%  
Depreciation Rs m1,425412 345.5%   
Interest Rs m1396 13.9%   
Profit before tax Rs m12,3132,088 589.7%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543469 755.3%   
Profit after tax Rs m8,7701,619 541.8%  
Gross profit margin %32.416.4 198.1%  
Effective tax rate %28.822.5 128.1%   
Net profit margin %22.512.9 174.7%  
BALANCE SHEET DATA
Current assets Rs m45,3517,778 583.1%   
Current liabilities Rs m6,5074,358 149.3%   
Net working cap to sales %99.827.2 366.4%  
Current ratio x7.01.8 390.5%  
Inventory Days Days12755 231.7%  
Debtors Days Days9580 118.9%  
Net fixed assets Rs m21,1605,713 370.4%   
Share capital Rs m531170 313.0%   
"Free" reserves Rs m58,62510,547 555.9%   
Net worth Rs m59,15610,937 540.9%   
Long term debt Rs m00-   
Total assets Rs m67,83215,574 435.5%  
Interest coverage x926.822.8 4,061.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.8 71.2%   
Return on assets %12.911.0 117.6%  
Return on equity %14.814.8 100.2%  
Return on capital %20.820.0 104.4%  
Exports to sales %048.7 0.0%   
Imports to sales %21.87.1 308.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs m8,485889 954.8%   
Fx inflow Rs m32,3596,169 524.5%   
Fx outflow Rs m9,0421,285 703.6%   
Net fx Rs m23,3174,884 477.4%   
CASH FLOW
From Operations Rs m7,7591,397 555.5%  
From Investments Rs m-4,783-320 1,493.3%  
From Financial Activity Rs m-3,142-1,196 262.7%  
Net Cashflow Rs m-166-102 162.3%  

Share Holding

Indian Promoters % 52.0 55.4 93.9%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 11.8 3.4 348.1%  
FIIs % 19.0 3.9 487.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 37.0 46.5%  
Shareholders   31,796 30,437 104.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  MERCK LTD  NOVARTIS  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Dec 14, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS